Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

DB15680ApprovedInvestigationalVaccines

This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. It is approved for use in individuals 10...

Primary indication
This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.Curator reviewed · 6 structured indications
First approval
Canada, 2020 · United States, 2020 · European Union, 2021
Also known as
Nimenrix component neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
Brand names
  • Menquadfi
  • Nimenrix
  • Penbraya

Resolves to

Compound
UNIIT4GYX3110D
Clinical / RWD
RxNorm2360571

What you can answer from here — as of April 02, 2025

16Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
12Marketed productsAcross 4 countries and 4 labellers
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In